Redefining Bone Healing with NeoBoneSculpt
Team: Ankita Raja Shinde (Tandon ’25)
About the Venture:Â NeoBoneSculpt is a patient-specific bone implant for orthopedic oncologists that restores critical-size defects, controls infection, and prevents tumor recurrence using 3D-printed, drug-eluting, magnetic-hyperthermia regenerative scaffolds
Tell us about NeoBoneSculpt and the problem it aims to solve.
NeoBoneScuplt is a personalized, multifunctional 3D-printed implant platform for the treatment of complex bone defects following tumor resection and other high-risk reconstructive procedures. Today, treating large bone defects in orthopedic oncology and complex trauma surgery involves a fragmented, primarily structural approach. Metal implants, bone grafts, and synthetic materials are used to regain stability, but they don’t effectively address any remaining disease (tumor recurrence) or the local biological environment of the defect. Clinicians currently combine structural implants, systemic chemotherapy or antibiotics, and many revision surgeries, resulting in a “patchwork” care process. This approach manages structure, biology, and disease independently, despite the fact that the core clinical issue is ‌interconnected. NeoBoneSculpt challenges that fragmented model by integrating bone regeneration, localized drug delivery, and tumor-targeting capability into a single patient-specific implant.
What inspired you to take this step into entrepreneurship?
As a child, I always enjoyed solving problems. When I encounter an unsolved challenge, I’m driven to get to its core and won’t stop until it’s resolved. However, the problem isn’t truly over when a solution is found; it ends when that solution is put into practice, allowing for a real difference to be seen. Entrepreneurship offers the opportunity to do just that. It allows you to see that your solution is more than just an idea; it can actually help address real-world issues, which I find absolutely fascinating.
What sets NeoBoneSculpt apart?
The current market is fragmented, offering separate solutions for structural support, drug delivery, and tumor treatment—without a fully integrated approach. NeoBoneSculpt addresses this gap with a multifunctional, patient-specific implant that combines anatomical fit, bone regeneration, controlled drug delivery, and magnetic hyperthermia, tailored for high-acuity orthopedic oncology and complex defect reconstruction.
What motivated you to apply to the Challenge?
The NYU Entrepreneur Challenge is a distinctive program designed to support entrepreneurs at every stage of their venture’s growth. As a postdoc embarking on an entrepreneurial path, I found it incredibly beneficial due to its extensive knowledge base. It covers crucial topics such as financial modeling, marketing, and legal considerations, while also illuminating funding avenues and the expectations of venture capitalists. Participating in this cohort also allowed me to connect with exceptional peers at different points in their entrepreneurial journeys. I gained significant insights from their experiences, learning how they overcome obstacles and manage their businesses. While the prize money is certainly an attractive aspect, the program opens doors to numerous opportunities, regardless of winning. Ultimately, the true win lies in advancing your venture with the comprehensive knowledge and insights acquired from the coaches and mentors.
What has been the biggest turning point for you in your startup journey?Â
The turning point was when the project evolved from a PhD research concept into a venture. That shift forced me to think beyond technical performance to clinical workflow, patient outcomes, and market adoption.
 What have been the biggest challenges you’ve faced so far?
Translating a complex, multi-functional research concept into something clinically relevant and commercially viable has been a major hurdle. While optimizing materials is straightforward in a lab setting, surgeons in the real world prioritize workflow, reliability, and patient outcomes. To address this, we actively engaged with clinicians, holding over 35+ conversations that helped us simplify our value proposition and tailor the design to actual surgical requirements. Another challenge involved navigating the multidisciplinary nature of this technology, which spans materials science, drug delivery, and oncology. Rather than attempting to tackle everything simultaneously, we adopted a phased approach. We began by validating the structural and biological performance before integrating drug delivery and hyperthermia. Through programs such as NYU TVT, NSF I-corp regional, and mentorship, we’ve gained crucial insights that have guided our transition from a research project to a venture with a clear trajectory..
What are some recent milestones?
We’ve achieved key milestones including validating our multifunctional scaffold, filing a provisional patent, and conducting 35+ clinician interviews to refine our use case. We’ve also progressed through programs like TVT to shape our commercialization strategy. Currently, we’re focused on biological validation and narrowing our go-to-market in orthopedic oncology. It’s been challenging balancing technical depth with business decisions, but each step has helped de-risk the technology and move us closer to real clinical impact.
What advice would you give to aspiring entrepreneurs, especially those just starting out?
Start talking to your customers as early as possible. It’s easy to fall in love with your idea, but real insight comes from understanding the people you’re building for. Second, don’t try to solve everything at once. Focus on one clear problem and execute well—clarity and prioritization matter more than complexity. Finally, be prepared for uncertainty. Things will constantly change, and progress often feels slow. The key is to stay consistent, keep learning, and make decisions even when you don’t have perfect information.
